SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
Amendment No. __ *
INTERPHARM HOLDINGS, INC.
(Name of Issuer)
Common stock, par value $0.01 per share
(Title of Class of Securities)
460588106
(CUSIP Number)
Neil M. Kaufman
Davidoff Malito & Hutcher LLP
200 Garden City Plaza
Suite 315
Garden City, New York 11530
(516) 248-6400
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
June 15, 2005
(Date of Event Which Requires Filing of This Statement)
If
the filing person has previously filed a statement on Schedule 13G to report the
acquisition that is the subject of this Schedule 13D, and is filing this schedule
because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following
box. [ ]
*
|
The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment containing
information which would alter disclosures provided in a prior cover
page.
|
The
information required on the remainder of this cover page shall not be deemed to be
“filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 or otherwise subject to the liabilities of that section of the Act but shall be
subject to all other provisions of the Act (however, see the Notes).
Page
1 of 7
CUSIP No.
460588106
|
Page 2 of 7
|
1)
|
Names of Reporting Persons
|
|
|
|
P&K Holdings I, LLC
|
|
|
|
|
|
|
|
|
|
2)
|
Check the Appropriate Box if a Member of a group (See
Instructions)
|
|
(a) [ ]
|
|
(b) [X ]
|
|
|
|
3)
|
SEC Use Only
|
|
|
|
|
|
4)
|
Source of Funds (See Instructions)
|
OO
|
|
|
|
|
5)
|
Check if Disclosure of Legal Proceedings is Required
Pursuant to Items 2(d) or 2(e)
|
o
|
|
|
|
|
6)
|
Citizenship or Place of Organization
|
New York
|
|
|
|
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
WITH
|
7)
|
Sole Voting Power
|
8,014,928
|
|
|
|
|
|
|
8)
|
Shared Voting Power
|
0
|
|
|
|
|
|
|
9)
|
Sole Dispositive Power
|
8,014,928
|
|
|
|
|
|
|
10)
|
Shared Dispositive Power
|
0
|
|
|
|
|
|
|
11)
|
Aggregate Amount Beneficially Owned by Each Reporting
Person
|
8,014,928
|
|
|
|
|
12)
|
Check if Aggregate Amount in Row (11) Excludes Certain
Shares (See Instruction)
|
x
(1)
|
|
|
|
|
13)
|
Percent of Class Represented by Amount in Row
(11)
|
12.4% (2)
|
|
|
|
|
14)
|
Type of Reporting Person (See Instructions)
|
OO
|
|
|
|
|
|
|
|
|
|
CUSIP No.
460588106
|
Page 3 of 7
|
|
(1)
|
The Reporting Person disclaims beneficial ownership of any
of the shares held by Perry Sutaria.
|
|
(2)
|
Based on 64,609,554 shares of the Issuer’s common
stock, par value $.01 per share (the “Common Stock”)
outstanding as of September 27, 2006.
|
CUSIP No.
460588106
|
Page 4 of 7
|
Item 1. Security and Issuer
The
class of equity securities to which this Schedule 13D statement (the “Schedule
13D”) relates is the common stock, par value $0.01 per share (the “Common
Stock”) of Interpharm Holdings, Inc. (the “Issuer”). The
Issuer’s principal executive offices are located at 75 Adams Avenue, Hauppauge,
New York 11788.
Item 2.
|
Identity and Background
|
(a) - (c) This Schedule 13D is being filed on behalf of P&K Holdings
I, LLC, a New York limited liability company (the “Reporting Person”), with
its principal business address at 2 Shady Lane, Syosset, New York 11791. The principal
business of the Reporting Person is to provide structured and centralized management of
family assets; to promote limited liability protection to the members; to promote
efficient and economic management of investment and other business assets including but
not limited to investing in property of all kinds, including, without limitation,
capital stock, depository receipts, investment companies, mutual funds, subscriptions,
warrants, bonds, notes, debentures, options and other securities of whatever kind and
nature and to engage in any other activity that a limited liability company can engage
in under applicable law.
Perry Sutaria (“Perry Sutaria”), the sole member and manager
of the Reporting Person, is presently a physician at Morristown Urology Associates
located at 261 James Street, Suite #1A, Morristown, New Jersey 07960.
(d)
Neither the Reporting Person, nor any individual otherwise identified in
Item 2 of this Schedule 13D, during the last five years, has been convicted in a
criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)
Neither the Reporting Person nor any individual otherwise identified in
Item 2 of this Schedule 13D, during the last five years, has been a party to a civil
proceeding of a judicial or administrative body of competent jurisdiction and as a
result of such proceeding were or are subject to a judgment, decree, or final order
enjoining future violations of, or prohibiting or mandating activities subject to,
Federal or state securities laws or finding any violation with respect to such
laws.
(f)
The Reporting Person is a New York limited liability company. Perry
Sutaria is a United States Citizen.
Item
3. Source and Amount of Funds
On June 15, 2005, Perry Sutaria contributed 1,174,148 shares of Common
Stock and 292,214 shares of Series K Convertible Preferred Stock of the Issuer (the
“Series K Stock”) to the Reporting Person in exchange for a membership
interest in the Reporting Person. On May 25, 2006, the Reporting Person converted the
Series K Stock into an aggregate of 6,274,780 shares of Common Stock of the
Issuer.
Item
4. Purpose of Transaction
Perry Sutaria contributed the securities reported in this Schedule 13D
to the Reporting Person in furtherance of the management of family assets. On April 4,
2006, Perry Sutaria was elected the sole manager of the Reporting Person and has the
authority to control the assets of the Reporting Person, including the ability to vote
and dispose the shares of Common Stock of the Issuer owned by the Reporting
Person.
CUSIP No.
460588106
|
Page 5 of 7
|
The Reporting Person may from time to time acquire additional shares of
Common Stock (or securities exercisable for or convertible into Common Stock) in the
open market or in privately negotiated transactions, subject to availability of Common
Stock at prices deemed favorable, the Issuer’s business or financial condition
and other factors and conditions the Reporting Person deems appropriate. Alternatively,
the Reporting Person may sell all or a portion of the Common Stock in privately
negotiated transactions or in the open market.
Except as described above in this Item 4, as of June 15, 2005, the
Reporting Person nor any individual otherwise identified in Item 2 of this Schedule 13D
has any present plans or proposals which relate to or would result in: (a) the
acquisition by any person of additional securities of the Issuer, or the disposition of
securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger,
reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a
sale or transfer or a material amount of assets of the Issuer or of any of its
subsidiaries; (d) any change in the present board of directors or management of the
Issuer, including any plans or proposals to change the number or term of directors or
to fill any existing vacancies on the board; (e) any material change in the present
capitalization or dividend policy of the Issuer; (f) any other material change in the
Issuer’s business or corporate structure; (g) changes in the Issuer’s
charter, bylaws or instruments corresponding thereto or other actions which may impede
the acquisition of control of the Issuer by any person; (h) causing a class of
securities of the Issuer to be delisted from a national securities exchange or to cease
to be authorized to be quoted in an inter-dealer quotation system of a registered
national securities association; (i) a class of equity securities of the Issuer
becoming eligible for termination of registration pursuant to Section 12(g)(4) of the
Securities Exchange Act of 1934; or (j) any action similar to any of those enumerated
above.
Item 5.
|
Interests in Securities of the Issuer
|
(a)
The aggregate percentage of shares of Common Stock reported as owned by
the Reporting Person is based upon 64,609,554 shares of Common Stock outstanding as of
September 27, 2006, which is the total number shares of Common Stock outstanding as of
such date as reported by the Issuer in its Annual Report on Form 10-K filed with the
SEC on September 28, 2006. Based on calculations made in accordance with Rule 13d-3(d),
the Reporting Person may be deemed to beneficially own 8,104,928 shares of Common Stock
(approximately 12.4% of the outstanding shares of Common Stock.
(b)
As of April 4, 2006, when he was elected to be the sole manager of the
Reporting Person, Perry Sutaria may be deemed to have sole power to direct the voting
and disposition of 8,014,928 shares of Common Stock beneficially owned by the Reporting
Person.
(c)
Neither the Reporting Person nor any person identified in Item 2 in this
Schedule 13D, has effected, within the past sixty (60) days, any transactions in Common
Stock or securities convertible into, exercisable for or exchangeable of the
Issuer.
(d)
The members of the Reporting Person have the right to participate in the
receipt of dividends from, or proceeds from the sale of, the shares of Common Stock
held for the account of the Reporting Person.
CUSIP No.
460588106
|
Page 6 of 7
|
Item 6.
|
Contracts, Arrangements, Understandings or Relationships
With Respect to Securities of the Issuer.
|
The information in Item 4 is incorporated herein by
reference.
|
Item 7.
|
Material to be Filed as Exhibits
|
None.
CUSIP No.
460588106
|
Page 7 of 7
|
Signature
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: May 7, 2008
P&K
HOLDINGS I, LLC
|
|
|
|
|
By:
|
/s/ Perry Sutaria
|
|
|
|
|
Perry Sutaria
|
|
|
|
|
Manager
|
|
|
|